119 related articles for article (PubMed ID: 27519213)
1. DNA Topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms.
Holden JA
Endocr Pathol; 1999 Jun; 10(2):97-102. PubMed ID: 27519213
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
Holden JA; Townsend JJ
Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260
[TBL] [Abstract][Full Text] [Related]
3. Human DNA topoisomerase II-alpha.
Martinchick J; Rahn M; Jolles C; Holden J
Int J Oncol; 1997 Jun; 10(6):1229-34. PubMed ID: 21533509
[TBL] [Abstract][Full Text] [Related]
4. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Staley BE; Samowitz WS; Bronstein IB; Holden JA
Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
[TBL] [Abstract][Full Text] [Related]
5. Human DNA-Topoisomerases - Diagnostic and Therapeutic Implications for Cancer.
Kellner U; Rudolph P; Parwaresch R
Onkologie; 2000 Oct; 23(5):424-430. PubMed ID: 11441236
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
Coleman LW; Bronstein IB; Holden JA
Anticancer Res; 2001; 21(2A):1167-72. PubMed ID: 11396158
[TBL] [Abstract][Full Text] [Related]
7. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Kim R; Ohi Y; Inoue H; Toge T
Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas.
Holden JA; Perkins SL; Snow GW; Kjeldsberg CR
Am J Clin Pathol; 1995 Jul; 104(1):54-9. PubMed ID: 7611182
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
[TBL] [Abstract][Full Text] [Related]
11. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
Holden JA
Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
Villman K; Ståhl E; Liljegren G; Tidefelt U; Karlsson MG
Mod Pathol; 2002 May; 15(5):486-91. PubMed ID: 12011253
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
[TBL] [Abstract][Full Text] [Related]
15. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
Tortora G; Ciardiello F; Damiano V; Pepe S; Bianco C; di Isernia G; Davies SL; North P; Harris AL; Hickson ID
Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886
[TBL] [Abstract][Full Text] [Related]
16. Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Gupta D; Bronstein IB; Holden JA
Hum Pathol; 2000 Feb; 31(2):214-9. PubMed ID: 10685636
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Yoshida M
Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
[TBL] [Abstract][Full Text] [Related]
18. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
19. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.
Bauman ME; Holden JA; Brown KA; Harker WG; Perkins SL
Mod Pathol; 1997 Mar; 10(3):168-75. PubMed ID: 9071722
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II alpha expression in esophageal squamous cell carcinoma.
Ohashi Y; Sasano H; Yamaki H; Shizawa S; Kikuchi A; Shineha R; Akaishi T; Satomi S; Nagura H
Anticancer Res; 1999; 19(3A):1873-80. PubMed ID: 10470130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
